AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 152 min read$PHVS

Modig Berndt sold $80K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,292 shares of Pharvaris N.V. (PHVS) at $34.97 on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Jul 15, 2026, 5:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 5:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The CEO’s open-market sale is disclosed with a stated pre-arranged 10b5-1 plan, which generally lowers the probability of a strong negative fundamental interpretation.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new business or financial datapoint in the text.

03

What to watch

The article does not disclose any concurrent operational updates, guidance changes, or clinical/regulatory milestones, so the trading signal is limited to sentiment.

Relevance 2/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-15) for a 2026-07-13 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

Pharvaris CEO Modig Berndt sold 2,292 shares in an open-market transaction on 2026-07-13 at $34.9714, per Form 4.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification or tax planning and may not reflect bearish expectations, especially under a 10b5-1 plan.

Key entities

  • issuer
    Pharvaris N.V.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • insider
    Modig Berndt

    CEO and director who executed the reported sale.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, reducing discretionary-signal strength.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min